Ken Kent

Gilead Sciences

Senior Vice President, Chemical Development and Manufacturing Operations

Ken Kent is Senior Vice President, Chemical Development and Manufacturing Operations, Gilead Sciences. He is responsible for Gilead’s entire drug-substance supply and oversees process R&D functions in Foster City, California and Edmonton, Alberta, Canada, as well as internal and outsourced manufacturing.

He played a critical role leading CDMOs in sourcing ingredients and scaling up production of the remdesivir drug substance, Gilead’s COVID-19 treatment, to speed up and increase production. Mr. Kent has contributed to the development and commercialization of more than 25 approved products while growing his career from developing new synthetic routes as a process chemist to increasing leadership responsibilities in cross-functional roles. He has built and led teams with a reputation for innovation, quality, and safety while also fostering inclusion and career development.

He joined Gilead in 1988. He is a member of the American Chemical Society and has published more than 10 papers and patents on the research he has conducted at Gilead.